Articles
 
Email Page
J&J, Pfizer Biosimilar Payer Policy Case Could Survive Motion to Dismiss but Proving Anticompetitiveness Remains Challenging, Experts Say
March 23, 2018
Shuan Sim and Manasi Vaidya
BioPharm Insight

Axinn counsel Suchira Ghosh was quoted in the BioPharm Insight article, "J&J, Pfizer Biosimilar Payer Policy Case Could Survive Motion to Dismiss but Proving Anticompetitiveness Remains Challenging, Experts Say."

The article discusses Pfizer's recent biosimilar antitrust lawsuit against Johnson & Johnson, which claims that the latter company uses exclusionary contracts and anticompetitive tactics. Suchira was quoted saying that, based on a precedent from the 3rd Circuit, in order to establish anticompetitiveness Pfizer would not only have to prove low prices, but also other aspects of exclusionary contracts.